Immunovia AB sets warrant exercise price, secures funds for US test launch and studies.
Immunovia AB has set an exercise price of SEK 0.46 for its warrants series TO 2, with the exercise period from January 2 to January 16, 2025. The company has secured around 65% of the warrant program, amounting to SEK 37.2 million, through subscriptions and guarantees. These funds will be used to launch a next-generation test in the US market later this year and to support clinical studies for reimbursement.
4 months ago
3 Articles
You have 12 free stories remaining this month. Subscribe anytime for unlimited access.